Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results

BACKGROUND: Thalidomide is active in multiple myeloma and is associated with minimal myelosuppression, making it a good candidate for induction therapy prior to high-dose therapy with autologous stem-cell transplantation. DESIGN AND METHODS: Oral cyclophosphamide, thalidomide, and dexamethasone was...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
Main Authors: Morgan, Gareth J., Davies, Faith E., Gregory, Walter M., Bell, Sue E., Szubert, Alexander J., Navarro Coy, Nuria, Cook, Gordon, Feyler, Sylvia, Johnson, Peter R.E., Rudin, Claudius, Drayson, Mark T., Owen, Roger G., Ross, Fiona M., Russell, Nigel H., Jackson, Graham H., Child, J. Anthony
פורמט: Artigo
שפה:Inglês
יצא לאור: Ferrata Storti Foundation 2012
נושאים:
Original Articles and Brief Reports
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC3291601/
https://ncbi.nlm.nih.gov/pubmed/22058209
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2011.043372
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים